Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)

Volume 13, 4 Issues, 2017

Download PDF Flyer

Current Cardiology Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Jian'an Wang
School of Medicine Zhejiang University

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Can Lipoprotein-associated Phospholipase A2 be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?

Current Cardiology Reviews, 9(4): 310-315.

Author(s): Sine Holst-Albrechtsen, Maria Kjaergaard, Anh-Nhi Thi Huynh, Johanne Kragh Sorensen, Susanne Hosbond and Mads Nybo.

Affiliation: Dept. of Clinical Biochemistry and Pharmacology, Odense University Hospital, Sdr. Boulevard 29, DK-5000 Odense, Denmark.


Studies indicate that elevated plasma concentrations of lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with increased risk of cardiovascular disease. Lp-PLA2 seems to play a crucial role in the formation of plaques and acute inflammation, and plasma Lp-PLA2 could therefore potentially be used as a predictor of long-term outcome in ACS patients. To evaluate this, data concerning Lp-PLA2 as a predictor in ACS patients was gathered through a systematic literature review, and studies on this issue were extracted from relevant databases, incl. PubMed and Cochrane. A total of 14 articles were retrieved, but after thorough evaluation and elimination of irrelevant articles only seven studies were eligible for the literature review. All studies except two showed significant correlation between Lp-PLA2 and CV events in ACS patients. Only one study found an independent value to predict CV events 30 days after ACS. Altogether, there was inconsistency in the findings regarding the potential use of Lp-PLA2 and a lack of knowledge on several issues. Lp-PLA2 seems to give valuable information on which ACS patients are prone to new events and also provides important information on plaque size. However, more focused studies concerning genetic variations, time-window impact, patients with and without CV risk factors (e.g. diabetes), and treatment effects are needed. In conclusion, Lp-PLA2 offers new insight in the pathophysiological development of ACS, but until the aforementioned issues are addressed the biomarker will mainly be of interest in a research setting, not as a predictive parameter in a clinical setting.


Acute coronary syndrome, biomarker, Lp-PLA<sub>2</sub>, mortality, plaque rupture, prospective studies, statins.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 4
First Page: 310
Last Page: 315
Page Count: 6
DOI: 10.2174/1573403X09666131202143349
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science